While our data establish that continuous exposure to an anti-EGFR agent can select for EGFR ectodomain mutations that are associated with low affinity to that agent or EGFR, full validation of the significance of these mutants will require combinations of site-directed mutagenesis and wild-type EGFR knockout experiments in additional patient-derived H&N cancer cell lines. Here, EGFR is linked to cancer.